Journal profile · Medicine-Oncology
NAR Cancer
ISSN 2632-8674 · Oxford University Press · United Kingdom
NAR Cancer: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 97 (journal website); fully open access; APC about USD 2,391; median 146 days to acceptance (91 articles, last 24 months); 59 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
NAR Cancer is published by Oxford University Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are DNA Repair Mechanisms, RNA modifications and cancer and Cancer Genomics and Diagnostics, together about 33.7% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
NAR Cancer is a fully open access journal publishing original research and Critical Reviews and Perspectives articles at the intersection of the nucleic acids research and cancer fields, including cancer computational biology and data resources, DNA damage sensing and repair, gene regulation and chromatin, genomics, methods, nucleic acid-based therapeutics, and structural biology. Journal metrics Citation metrics Clarivate 2025 Impact Factor 4.6 2025 5 Year Impact Factor 4.7 Biochemistry & Molecular Biology (Rank by Impact Factor) 97/328 Oncology (Rank by Impact Factor) 101/333 2025 Cited Half-Life 3.4 years 2025 Immediacy Index 0.4 2025 Eigenfactor Score 0.00312 2025 Article Influence Score 1.696 Scopus 2025 CiteScore 5.9 Oncology (Rank by CiteScore) 114/428 Cancer Research (Rank by CiteScore) 98/233 2025 Source Normalized Impact per Paper (SNIP) 0.841 Google Scholar h5-index 23 Readership 2025 Full Text Usage 145,445 Peer Review and Production 2025 Median days from submission to first decision 32.5 days 2025 Median days from submission to final decision 95 days About metrics Abstracting and indexing services NAR Cancer is covered by the following indexing services: Baidu Cross Ref DataSalon DeepDyve Digital Science EBSCO Ex Libris PMCFull Portico Portico Article ProQuest OA Switchboard OCLC Scopus Web Of Science Disclaimer Statements of fact and opinion in the articles in NAR Cancer are those of the respective authors and contributors and not of the Journal or Oxford University Press. Neither Oxford University Press nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief William DynanPublisher website
Editorial board by country: 4 in mainland China (about 6%); most named United States 33, United Kingdom 6, Mainland China 4, Germany 4, Italy 4 (63 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- DNA Repair MechanismsBiochemistry, Genetics and Molecular Biology14%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology11.9%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7.8%
- RNA Research and SplicingBiochemistry, Genetics and Molecular Biology6.7%
- PARP inhibition in cancer therapyMedicine6.6%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.5%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology5.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPubMedPublisher website
Other: EBSCO, ProQuest, Baidu, OCLC, Portico
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 97Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.7Publisher website ·
- CiteScore 2026-06
- 5.9LetPub ·
- CiteScore (publisher) 2025
- 5.9Publisher website ·
- SJR 2026-06
- 2.02LetPub ·
- SNIP 2026-06
- 0.84LetPub ·
- h-index
- 35OpenAlex ·
- i10-index
- 162OpenAlex ·
- 2-year mean citedness
- 5.68OpenAlex ·
- Self-citation rate
- 2.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 56LetPub ·
- Downloads per year (publisher) 2025
- 145,445Publisher website ·
Articles by year OpenAlex count · 339 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 26 | 26 | 14 |
| 2025 | 59 | 59 | 181 |
| 2024 | 50 | 50 | 572 |
| 2023 | 63 | 63 | 825 |
| 2022 | 45 | 45 | 770 |
| 2021 | 57 | 57 | 1,422 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
146 daysMedian, submission to acceptance · P25–P75 113 days – 189 days
- Acceptance to online
- median 29 days (91 articles)
- Submission to online
- median 180 days
- Sample
- 91 articles with submission and acceptance dates (94 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Submission to first decision 2025
- 32.5 daysPublisher website ·
- Submission to final decision 2025
- 95 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,391 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,583 | — | — | |
| LetPub | USD 2,391 | Yes | — |
Other charges and waivers (author guidelines)
- Colour charges
- No colour charges
- Page charges
- No page charges
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6, with length limits
- original researchNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…Length not stated
- perspectiveNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…Length not stated
- reviewNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…Length not stated
- review articleNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…figures and tables ≤ 6 · references ≤ 150
- short reviewNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…Length not stated
- standard articleNAR Cancer publishes Standard, Review, and Cancer Data Resource articles. Standard articles Standard articles report original research results. Manuscripts shou…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, Open access, Peer review, Preprints, Self-archiving
- Authorship Authorship
Authorship is limited to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. The Journal will contact all listed authors at the point of submission to confirm their role. Authorship should be based on (i) substantial contri…
Source ↗Publisher website ·- Conflicts of interest Disclosure of potential conflicts of interest
Authors The Journal requires all authors to disclose any potential conflict of interest at the point of submission. It is the responsibility of the corresponding author to ensure that conflicts of interest of all authors are declared to the Journal. A conflict of interest exists when the position, activities, or relationships of an individual, whether direct or indirect, financial or non-financial…
Source ↗Publisher website ·- Data availability Availability of data and materials
Data availability statement required at submission Model summary
The Journal requires all authors, where ethically possible, to publicly release all data and software code underlying any published paper as a condition of publication. Authors are required to include a data availability statement in their paper. When data and software underlying the research article are available in an online source, authors should include a full citation in their reference list.…
Source ↗Publisher website ·- Publication ethics Screening for misconduct
Manuscripts may be screened using iThenticate to help detect publication misconduct including plagiarism and redundant publication. The Journal uses ScholarOne's Unusual Activity Detection tool to build confidence in the identity of authors and reviewers. Manuscripts may also be screened, including with services provided by third parties, to help detect integrity issues such as inappropriate image…
Source ↗Publisher website ·- Open access Open access charges
Please see the details of open access licences and charges. As the Journal is fully open access, you must pay the open access charge or request to use an institutional agreement to pay the open access charge through our licencing and payment portal, SciPris. Please note that prices are subject to change. All stated charges are exclusive of any applicable value added tax, goods and services tax and…
Source ↗Publisher website ·- Peer review Peer review process
Single-anonymized peer review Model summary
The Journal uses the ANSI/NISO Standard Terminology for Peer Review. If you would like further description of the peer review terms used here, please refer to the most recent standard definitions. If further clarification is needed, please contact the editorial office at narcancer.editorialoffice@oup.com. Peer review summary: Identity transparency: single anonymized Reviewer interacts with: editor…
Source ↗Publisher website ·- Preprints Preprints
Preprint policy allows preprints Model summary
As an author, you retain the right to make an Author’s Original Version (preprint) available through various channels and this does not prevent submission to the Journal. If accepted, you are required to update the status of any preprint, including adding your published paper’s DOI. For full details on allowed channels and updating your preprint, please see our Author self-archiving policy.
Source ↗Publisher website ·- Self-archiving Self-archiving
Self-archiving refers to posting a copy of your work on a publicly accessible website or repository. Under certain circumstances, you may self-archive versions of your work on your own webpages, on institutional webpages, and in other repositories. For information about the Journal's policy, and to learn which version(s) of your paper are acceptable for self-archiving, please see our Author self-a…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2632-8674
- Latest issue on the website
- Volume 8, Issue 3 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about NAR Cancer
What CAS zone is NAR Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, NAR Cancer is in Zone 4 of Medicine, and in Zone 4 of the minor category Biochemistry & Molecular Biology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of NAR Cancer?
The journal's website gives an impact factor of 97 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.9, h-index 35.
How long does peer review take at NAR Cancer?
Based on the dates recorded on 91 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 146 days (interquartile range 113–189 days); authors report an average review time of about 13 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of NAR Cancer based?
Of the 63 board members whose country the journal's board page names, 4 (about 6%) are in mainland China; the countries named most often are United States (33), United Kingdom (6) and Mainland China (4). Counted from the institutions listed on the board page; for reference only.
Which databases index NAR Cancer?
According to LetPub and DOAJ records, NAR Cancer is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science, PMC and PubMed; that list has not been checked against each database.
Is NAR Cancer open access, and what is the APC?
NAR Cancer is a fully open-access journal. APC about USD 2,391.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .